Join our daily newsletter At The Bell to receive exclusive market insights
LTR Pharma (ASX:LTP) has launched an online men’s health platform to “facilitate the regulated prescription” of its nasal spray Viagra product.
Called SPONTAN, the company’s flagship product – which originally landed it on the radars of investment bank analysts when it floated on the market, not just retail – is a fast-acting Viagra alternative that is applied as a nasal spray.
But that interest from investment bank analysts (at least one of whom initiated coverage on the stock) comes with responsibilities – in other words: Live up to the hype.
And that may be a problem for LTP right now. After touching $2/sh in October, the company’s share price has since sunk to 93cps – it listed last December just above 30cps.
The price jumped to $1.88/sh in August after the first patient was prescribed SPONTAN under the TGA, but then after hitting $2, it looks like something changed the mood in the room.
(Read: No further hard news around prescriptions.)
Enter the e-store – or telehealth service, depending on how you look at it. To be fair, it’s both. Existing partner Restorative Health Clinic (RHC) is helping to launch the service.
“This early launch by our joint venture partner demonstrates strong market demand for innovative healthcare solutions in men’s health,” LTR Pharma EC Lee Rodne said.
“The platform provides an additional channel for delivering treatments, including SPONTAN, to Australian men via early access scheme pathways.
“We look forward to working with the RHC team to support the delivery of professional healthcare services in this growing online market.”
LTP last traded at 93cps.
Join the discussion: See what HotCopper users are saying about LTR Pharma and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
